Yeah. I just wanted to point out on the numbers. As Veli-Matti said, on the clinical side, we grew 60%. So overall growth was 2%. But the devil here is in the details as well.
So that we decided to go into the clinical market, we decided to build a portfolio for that market and also captured the first big customers.
And on that roadmap. So we've been moving forward very, very well. So. And because if we look at the profitability on a research side and a clinical side, obviously we see that the profit will come from the clinical side. And now we have kind of taken the first steps on that side of the business. And it seems to be growing quite nicely.
But this strategy. So, I've been showing this slide a few times, but it's still very valid.
So there's an active problem recognition.
So, our customers, they know that they need something. So they're actively looking for solutions.
That's why the large flagship hospitals are really important. And the reference value they gave is really, really important in this phase so that someone can show what the best practice is, how it will be delivered, what type of components, and what type of solutions you need to build a kind of working model. And demand is going up. So the cancer rates are going up. Aging population, all of those same basic factors are present, and also the capacity. In different continents and countries, there is no situation where there is an overcapacity of pathologists.
So there would be an overcapacity of pathologists. So there is a need and that need is growing.
So our kind of play or place in this workflow. So we are talking about the physical samples, where if there is a prediction that you might have cancer, it leads to a tissue sample, which will be prepared and scanned. And then it comes to a software piece which is responsible for uploading those images, sharing them with pathologists, and storing them. And what currently drives the market forward is AI. And that's the area where we are. So we are the ones who understand what's on those samples. So we can extract the information from those huge files, even though they are physically small. But we are talking about images that are two gigabytes in size. And then you are looking for really, really tiny details.
But what Aiforia can do here is remarkable. So we do it much better than any of our competition, as we not only provide heat maps, but we also go deeper. So we do a quantitative analysis. We populate the report.
We actually give the information that the pathologist needs for their decision making. And that is in hot demand at the moment. So, that drives the demand for the image management vendors, the software vendors.
And that drives the demand for the scanner vendors as well.
Of course, if you turn it around, scanner penetration is an important piece as well, so that they have the devices to actually obtain the digital images and then use an AI. So all in all, they are connected to each other. So what we have, we have the technology leadership. So we use the foundation models, Transformers.
We use CNN, which is the latest technology as well, and it is already working and deployed. So we are recognized as a leader on this side. So we have a scalable business model. Now we have a couple of customers moving from the first phase to the phase where they are actually using the software and paying for the usage. So, and that's a profitable part for us because in the first phase, you need to invest in selling. You need to invest in delivering the solution. But once it's there and the customer is ready, you can add more AI models and scale up the usage, which is good for the software company's interoperability. As I said. So we are connecting with multiple systems. And we have interoperability agreements and testing done with multiple scanners and multiple image management systems. And the last point, this is something substantial. So I would like everyone to focus on this as well. So it's a certified quality to be able to operate in the US hosting patient data, you need to have HIPAA compliance. So you need to have multiple different kinds of security regulations and certifications in place. You need to have some patents.
And now you need to have the IVDR regulated products and CE-IVD products under that, meaning that it's a heavy investment. So, this is a barrier to entry for this industry for sure. Because anyone who wants to enter this industry, it takes time to obtain all of those certifications. Then we have it, and we can now start selling in volume on that side. Just a visualization of our differences.
But we've been looking at the main areas where we want to partner with. So, I have to say we have a pretty good offering at the moment. And that's the broadest offering in the market at the moment. So, and then of course we have a pipeline of new, upcoming products as well. And this is an interesting picture because four years ago when we did the IPO, we said, okay, we didn't have any CE-IVD in those days.
And we said, okay, our strategy is to build a portfolio of solutions that allows users to cover 80% of the workflow. So we decided that we bring all the relevant solutions with high quality, and we aim for 80% coverage by the end of a decade.
So currently, we have a 60% coverage.
So we cover all the major disease areas in pathology. So this is something that, as a company, we are really, really proud of, and of course, we are now working on increasing the number closer to 80. But we are well on track to meet that target.
And then coming back to the growth rate of 2% versus 60%. So, I picked the 60% because we've been focusing on getting these flagship customers in place and growing the clinical business, as this gives us the opportunity to scale up significantly. In 2021, we secured the Mayo Clinic, and then we developed those solutions.
So there were three closings in Q1 2023. This, by the way, is not all the closings, but these are the ones that we've been focusing on because we also set a target to have 15 types of customers where there's potential revenue over half a million. So, annual recurring revenue is over half a million. So that it doesn't happen in the first year. So, there's an opportunity to build up those customer relations at that level. And last year, there were five closings. A really interesting one I mentioned is Castilla y León. Interesting one. And that's a fantastic deal. So it's a big region in Spain.
First good referenceable customers together with the Swedish image management vendor sector.
So it's a fantastic deal.
The challenge there was that they wanted to have a local implementation.
So now we are delivering that.
So it will happen in Q3.
But also, that was impacting a little bit on the revenue that we could book in the first half of the year, so we actually could have done a little bit better on a Rev Rex. But the main point is that it will now be delivered, and we provide a fantastic solution to the end customer. But those are the closings from last year and this year. So five meaningful closings in the first half of the year.
And you can show that. See that, okay. France is really picking up.
So, a couple of hospitals from the Assistance Publique-Hôpitaux De Paris. So we want the Nantes region. So a really good reference. And they have already announced that they are using Aiforia. And we got the deal.
So that's why it's on a list. But really, it was a series of nice closings.
And Lombardia is, of course, commercially also a significant player.
So, moving forward, and so far, every tender that we've participated in, we have been winning. In some cases, they've chosen one or two other vendors for the same tender, but we haven't lost any, so that's good to keep in mind as well.
And going forward, I know there are questions coming, such as how do we accelerate. So where, or rather when, do we actually see the revenue growth happening? So, we had a big strategy exercise a couple of months ago. And the outcome is that, okay, we see the opportunity in Europe.
The scanner penetration is approximately 30% in Europe. So, it sounds low but significant. But okay. So it's actually much better than elsewhere in the world. And then we see these public fundings speeding up the adoption. And that's why, as a European company, it's natural that we want to capture that opportunity and accelerate the business in Europe.
We will grow the clinical offering.
So there will be more CE-IVD marked solutions coming up. And we look at other kinds of opportunities, considering how we can improve the user experience close to our core and domain. So, but we've been obviously planning all of these different areas. So, how much revenue and what type of growth will come from those areas? But this is at a high level, considering both short-term and long-term aspects. This is obviously truly a global business.
We have a good presence in the US, so we want to capitalize on that and start investing again in the US.
Uh, going forward.
Then we have some interesting ones.
So I mentioned that when you talk about AI currently, what we offer is efficiency. You can do much more with the same resources. You can do it with better quality. You avoid mistakes.
But the other thing is that now the prognostic models are advancing rapidly and showing significant potential in improving outcomes. What we've built with the Mayo Clinic allows for the prediction of patient outcomes. Combining the Bayesian data, integrating it with AI-driven data. This is something that builds up the value of AI.
First, the efficiency aspect. But now the additional value is coming from things that you can't really do with the human eye. So then we have also been talking with a couple of pharmaceutical customers. And by the way, I didn't mention that Orion was a nice win from Finland on that side where we sell an Aiforia study solution. So that's in good shape. But in the context of pharma, we're referring to companion diagnostics.
And we've been proactively approached by a couple of very large pharma companies who are considering that when they are developing a medicine, they need to integrate AI so that AI can drive certain results based on that outcome. So, you can then provide certain treatments or specific medicines to the patients or implement companion diagnostic approaches, but those are long-term initiatives. So that's why I put it in 2030, even though some of those discussions have already started.
But this is a really interesting marketplace.
And there's a good opportunity to make it a really nice business. That's it from my side.
And now there's room for some questions.
I know that Antti is already ready.